Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Metsera, Inc. ( (MTSR) ) has issued an announcement.
On November 5, 2025, Metsera, Inc. issued a statement regarding a legal ruling in its ongoing litigation with Pfizer Inc. The Delaware Court of Chancery denied Pfizer’s request for a temporary restraining order against Metsera’s Board of Directors. Metsera expressed satisfaction with the ruling and criticized Pfizer’s litigation efforts as baseless. The company affirmed its commitment to act in the best interests of its shareholders and patients.
The most recent analyst rating on (MTSR) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on Metsera, Inc. stock, see the MTSR Stock Forecast page.
Spark’s Take on MTSR Stock
According to Spark, TipRanks’ AI Analyst, MTSR is a Underperform.
Metsera, Inc. faces significant challenges, primarily due to its lack of revenue and ongoing financial losses, which are critical concerns for long-term viability. The technical analysis indicates bearish momentum, reinforcing negative sentiment. Valuation metrics are limited, as the company does not have earnings or dividends. Despite a strong cash position, the high cash burn rate poses a risk. Overall, the lack of revenue and negative technical indicators weigh heavily on the stock’s potential.
To see Spark’s full report on MTSR stock, click here.
More about Metsera, Inc.
Average Trading Volume: 2,497,581
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.71B
See more data about MTSR stock on TipRanks’ Stock Analysis page.